Amgen’s Aranesp Faces More Labeling Changes As A Result Of Safety Concerns
FDA advisory panel meeting also slated for Q1 2008 as part of pharmacovigilance review of ESAs.
FDA advisory panel meeting also slated for Q1 2008 as part of pharmacovigilance review of ESAs.